The Manufacturers Life Insurance Company Sells 1,013,192 Shares of Becton, Dickinson and Company $BDX

The Manufacturers Life Insurance Company lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 42.5% during the 1st quarter, Holdings Channel reports. The firm owned 1,371,180 shares of the medical instruments supplier’s stock after selling 1,013,192 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Becton, Dickinson and Company were worth $215,591,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth about $25,000. Steph & Co. boosted its stake in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 65 shares during the last quarter. SHP Wealth Management bought a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at approximately $29,000. Finally, WPG Advisers LLC grew its holdings in Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 4.6%

Shares of NYSE BDX opened at $166.21 on Wednesday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The business’s 50 day moving average is $150.67 and its two-hundred day moving average is $164.15. The stock has a market capitalization of $45.80 billion, a P/E ratio of 42.08, a PEG ratio of 11.24 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the company earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Piper Sandler decreased their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. TD Cowen decreased their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. Finally, Stifel Nicolaus lowered their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $180.93.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at $16,122,355.05. This trade represents a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,189 shares of company stock valued at $765,661 over the last ninety days. 0.40% of the stock is owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.